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SUMMARY 
Synthetic routes are described to 5,6-diamino-
2,4'-bipyrimidin-4-ones and 4,5,6-triamino-2,4'-
bipyrimidines, as key intermediates from the 
corresponding pyrimidine-4-carboxamidinium chlorides, 
and their subsequent conversions into 2-(pyrimidin-4'-
yl)purines, 2-(pyrimidin-4'-yl)pteridines, 2-
(pyrimidin-4'-yl)quinazolines, and 5-(pyrimidin-4'-yl)-
(lH)-v-triazolo[4,5-d]pyrimidin-7(6H)-ones, some of 
which bear a sulfur- or nitrogen-linked basic side 
chain. 
Synthetic routes are also described to a series of 
2, 6- and 8-phenylpurines, in which one hetero-ring has 
been replaced by an homocyclic system, each having an 
appropriate S- or NH-linked side chain elsewhere in the 
molecule; to 2- and 4-phenylpteridines, each with a 
similar side chain and some with two additional C-methyl 
groups; to 2- and 4-phenylquinazolines, each equipped 
with an analogous side chain; and to the 2-(pyridin~4'­
yl)purine and 2-(pyridin-4'-yl)quinazoline analogues of 
the above. 
lV 
The annelation of a (fused) imidazole ring to one 
pyrimidine ring of a 2,4'-bipyrimidine bearing a suitable 
side chain, had little effect on activities as amplifiers 
of phleomycin-G in an in vitro bacterial system; 
relocation of the basic side chain from the 6- to the 
8-position in the resulting pyrimidinylpurines had a 
mildly deleterious effect. 
The 2-phenylpurines, 2-phenylpteridines, and 
2-phenylquinazolines with appropriate s- or NH-linked 
side chains are shown to have considerable activity, 
but isomers and methylthio analogues showed less 
activity while the 2-pyridin-4'-yl analogues could not 
be evaluated because of intrinsic antibacterial activity. 
v 
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CHAPTER I 
INTRODUCTION 
1-1 Phleomycin and Related Antibiotics 
Phleomycin and related antibiotics l - 3 were isolated 
as Cu (II) complexes from the culture media of Streptomyces 
verticillus and proved to have wide-spectrum antimicrobial 
and some antitumor activity. 4-9 The copper in phleomycin 
can be removed by 8-hydroxyquinoline but this process 
does not affect the above activities. 10 The phleomycin 
molecule consists of four parts: 
(i) a two-sugar portion; 
(ii) a polypeptide portion containing a pyrimidine 
and imidazole rlng; 
( iii) a dihydrobithiazole portion; and 
(iv) a polybasic side chain (see Fig. 1-1) .2,11-13 
Related antibiotics 3 ,14 have closely similar structures. 
For example, bleomycins have a bithiazole instead of a 
dihydrobithiozole portion and phleomycins can therefore 
be converted by chemical oxidation with manganese dioxide 
into bleomycins. 2 ,11 The polybasic side chain varles 
somewhat in individual phleomycins according to the 
nutrient precursors available in the culture medium; also 
in bleomycins. 11 ,12 In 1978, the portion attached to 
the 2-position of the pyrimidine ring was revised: the 
supposed S-lactam ring turned out to be a pseudodipeptide, 
based on studies of the 13 C n.m.r. spectra. IS The Cu 
(II)-complex of bleomycin (see Fig. 1-2) is based firmly 
on X-ray crystallographic analysis. 16 
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Phleomycins and related antibiotics inhibit 
selectively DNA synthesis in bacteria and in cancer 
cells. 17 - 19 Recent in vitro studies of the 
mechanism, by which phleomycin and related antibiotics 
act, suggest that initial intercalation into DNA is 
involved, followed by strand scission. 2 o - 23 
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1-2 Amplification of Phleomycin 
Indiction of DNA-breakdown and cell death occurs at 
low concentration (2 ~g/ml) of phleomycin in growing 
Esherichia coli but not in cells at stationary phase: 
at higher concentration (~10 ~g/ml), death occurs at all 
stages. 24 In 1970, G. W. Grigg25 observed that a high 
concentration of phleomycin had the same effect in 
E. coli as a combination of caffeine plus a lower 
concentration of phleomycin. Caffeine increased the 
lethal effects of the low concentration of phleomycin 
some 30-fold, but alone it had no effect on such a 
I " ~ I, culture. The term "amplification" was adopted for this 
phenomenon. 25 It appears that phleomycin attaches itself 
to single-stranded DNA,26,27 and thus distorts the 
secondary structure and thereby induces local denaturation 
in DNA. This leads to sensitization of the DNA to 
cellular endonucleases, and subsequent breakdown and 
death. 28- 3 0 Caffeine seems to react with such sensitized 
DNA to increase the frequency of denaturation and the 
subsequent breakdown and death of cells. Caffeine, which 
is synergistic with many DNA-damaging agents in causing 
lethality in mammalian cells,31,32 weakens normal 
hydrogen bonding of such denaturated regions of phleomycin-
treated DNA. C. C. Lau et al.,33 showed that caffeine 
potentiates the lethality of nitrogen-mustards by inducing 
damaged cells to undergo premature mitosis before 
repalrlng lesions in their DNA. 
1-3 Potential Uses for Amplified Phleomycin 
Phleomycin, like many antibiotic and other anti-
cancer drugs, produces toxic side effects at 
therapeutically effective dosage levels. 7 ,34-37 The 
most troublesome side effects of phleomycin are its 
nephrotoxicity and lung toxicity. However, since the 
effective dose of phleomycin can be reduced considerably 
by using it in conjunction with caffeine, this offers 
a way to reduce or even eliminate such side effects. 
A great many potential amplifiers have been prepared 
and screened for amplifying activity on a bacterial 
system in vitro during the last decade. 38 In addition, 
it was hoped that the amplifier might be taken up 
specifically by cancer cells or by pathogens and hence 
confer an increased specificity on the corresponding 
phleomycin-amplifier regimes. In fact, some of the 
more active compounds in the screen have been tested 
as adjuvants of phleomycin against several types of 
tumor in rats and mice, with appreciable success. 39 ,40 
5 
1-4 Amplifiers Unlike Caffeine 
G. W. Grigg et al.,29 observed that amplifying 
activity was shown by pyronine-Y, by a coumarin, and by 
a wide range of aromatic bi-, tri, and tetra-cyclic 
hydrocarbons which are cationic or which can become 
positively charged by protonation at an attached nitrogen 
substituent~l The general structural requirements for 
such amplifiers are shown in Fig. 1-3, but without the 
necessary substituents or heteroatom(s) . 
6 
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1-5 Fused Reterobicyclic Amplifiers 
1-5 A. Purines 
Following the original discovery that caffeine 
amplified phleomycin,24 more than one hundred related 
and unrelated purines were tried as amplifiers using 
Escherichia coli cultures in vitro (see Fig. 1-4) .29 
It was soon concluded that amplifiers must not only be 
high in activity, but that they should have good 
solubility in water, low toxicity, and a high resistance 
to metabolism. 38 It is hard to give a precise 
correlation between substituents on purine and resulting 
activity, but it is possible to draw some broad tentative 
conclusions: an anionic centre (e.g. OR, SR, C0 2R) and 
electron-withdrawing substituentSI such as a triflouro-
methyl group, both decreased activity; the presence of 
two C-methyl groups or an ethyl group in the molcule was 
essential for high activ ity; and alkylthio or 
dimethylamino substituents do assist activity. 
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1-5 B. Heteromonocyclic Compounds and 
Their Benzo Derivatives 
Pyrimidines, triazines, imidazoles, thiazoles, 
pyrazines and 1,2,4-triazoles, all with suitable 
substituents, were prepared and tested 42 - 44 in order to 
see whether a bicyclic or greater system was necessary 
for activity, or not (see Fig. 1-5). Only a few such 
compounds showed any appreciable activity, and the five-
membered heterocycles were almost lacking in activity. 
Benzimidazoles, benzothiazoles, benzoxazoles, 
quinazolines, and quinolines, i.e. the above monocyclic 
systems fused with a benzene ring, exhibited much 
improved activities, but nearly all of those tried had 
very poor solubilities (see Fig. 1-6) 43,45-4 8 
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1-5 C. Heterobicyclic Purine Analogues 
Thiazolo[5,4-d]pyrimidines, pyrazolo[3,4-d]-
pyrimidines, imidazo[4,5-b]pyridines, imidazo[4,5-c]-
pyridines, oxazolo[4,5-b]pyridine, imidazo[4,5-c]-
pyridazines, imidazo[4,5-b]pyrazines, and thiazolo-
[4,5-b]pyrazines were prepared and tested (see 
Fig. 1_7).42,44,46-48 
Many of the thiazolo[5,4-d]pyrimidines were 
w~ter 
very poorlyAsoluble but a few showed very high activity. 
Only one of pyrazolo[3,4-d]pyridine showed good activity. 
1madazo[4,5-b]pyridines and their [4,5-c] analogues were 
water 
moreAsoluble and showed quite high activities. 
Oxazolo[4,5-c]pyridazines and imidazo[4,5-b]pyrazines 
showed mediocre activity. 
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I-S D. s-Triazolopyridines and Related Systems 
s-Triazolo[4,3-a]pyridines, s-triazolo[4,3-a]-
pyrimidines, their Dimroth-rearranged [l,S-a] isomers, 
14 
s-triazolo[4,3-c]pyrimidines, s-triazolo[l,S-c]pyrimidines 
s-triazolo[3,4-b]benzothiazoles, and s-triazolo[3,4-i]-
purlnes were prepared and tested (see Fig. 1-8) .42,45,49-52 
This type of purine analogue, in which a nitrogen atom 
was shared between the five- and six-membered rings, 
reached very high activities with relatively good 
solubilities; in addition, they exhibited unusually 
low toxicities: one even showed on LDSO of >SOOO mg/kg 
in mice! Unlike many of the other systems, the 
triazolopyrimidines proved relatively stable in vivo 
and several appeared unchanged in the urine to the 
extent of SO% or more. 
for an amplifier. 
This is an obvious advantage 
i 
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1-6 Unfused Heterobicyclic Amplifiers 
1-6 A. Thiazolylpyridines 
The mechanism by which phleomycin and related 
antibiotics act, involves initial attachment to DNA by 
the basic side chain and intercalation of the bithiazole 
portion (see Fig. 1-9) .16 An attempt has been made to 
mimic these parts of the phleomycin molecule in the 
molcular design of some unfused heterobicyclic amplifiers. 
Thus, 2-, 3- or 4-(thiazol-4'-yl)pyridines, and 2-, 3-
or 4-(thiazol-2'-yl)pyridines were prepared and tested 53 - 55 
(see Fig. 10). 
The best activities were obtained in the (thiazol-
~ 
4'-yl) pyridine systems with a sulphur-linked basic side 
chain. Whether such highly active unfused heterobicyclic 
amplifiers bind strongly to DNA has yet to be shown. 
~ 
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1-6 B. Pyridinyl- and Pyrazolyl - pyrimidines 
2-Pyridin-2', -3' or -4'-ylpyrimidines, and 
4-pyrazol-l' or -4'-ylpyrimidines were prepared (see 
Fig. I-II) but only two compounds (with sulfur-linked 
side chains) reached a very high activity. 54-56 
'/ 
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1-6 C. Bipyrimidines and Miscellaneous Systems 
Derivatives of the three bipyrimidines, 4,5'-
bithiazoles, 4-(thien-2'-yl)pyrimidines, 4-(thiazol-2'-yl)-
pyrimidines, 2-(thiazol-4'-yl)pyrazines, and 4-phenyl-
thiazole were prepared (see Fig. 1-12) .53,54,56-58 
Only one compound in each of the bipyrimidine systems, 
one 4-(thien-2-yl)pyrimidine, and a 4-phenylthiazole 
reached very high activities. 
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1-7 Antitumor Activity of Phleomycin plus 
Heterocyclic Amplifiers 
Eight of the heterocyclic purine analogues, which 
showed reasonable activity as amplifiers in the in vitro 
screen, have been tested against three animal tumor 
models in mice (see Fig. 1-13) . 3 9,40 All compounds 
showed significant amplification of phleomycin against 
at least one tumor type. The dose levels of both the 
phleomycin and amplifier proved very important and the 
optimal levels varied widely with actual agents used. 
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11-1 
CHAPTER II 
SYNTHESIS OF SOME 
2-PYRIMIDINYL-HETEROBICYCLES 
Introduction 
Unfused heterobicyclic systems, such as the 
bipyrimidines, are known to enhance the activity of 
phleomycin as an antibacterial or antitumor l - 4 agent. 
However, heteromonocyclic compounds have little effect 
on activityS although systems in which such heterocycles 
are fused with a benzene ring (to give fused heterocyclic 
systems such as quinazoline) do show considerable 
activity. 6 To date, heterocyclic systems, in which 
one pyrimidine ring of a bipyrimidine is fused with 
a second heterocyclic ring, have not been prepared and 
tested as amplifiers of phleomycin. Hence a serles 
of pyrimidinyl-heterobicycles have now been prepared 
to represent such potential amplifiers. 
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11-2 Preparation of 2,4'-Bipyrimidines 
Treatment of 2-dimethylaminopyrimidine-4-carbonitrile 7 
(11.2), which was prepared from 2-chloropyrimidine-4-
carbonitrile 8 (11.1) by a known method, with methanolic 
sodium methoxide and ammonium chloride conveniently gave 
the amidinium chloride (11.3). Likewise, 2-chloropyrimidine-
4-carbonitrile 8 (11.1) was converted, by successive treatment 
with methanolic sodium methoxide and ammonium chloride, 
into the analoga~ s amidinium chloride (11.4) (Scheme II-I). 
Condensation of the above 2-dimethylaminopyrimidine-
4-carboxamidinium chloride (11.3) with ethyl cyanoacetate 
in ethanolic sodium ethoxide gave a separable mixture of 
the bipyrimidine (11.5) and the pyrimidinylacrylate (11.6) 
(Scheme 11-2). 
Nitrososation of the bipyrimidine (11.5) gave the 
S-nitrosobipyrimidine (11.7), but it proved more effective 
to make the nitroso der i vative (11.7) directly, and 
without any by-product, by condensing the amidine (11.3) 
with ethyl 2-cyano-2 -hydroxyiminoacetate. 9 In much the 
same way, the arnidine (II.4) gave the nitroso derivative 
(11.8) and the condensation of a-hydroxyiminoma1ononitri1e 10 
with the amidines (11.3,4) gave the nitroso derivatives 
(11.9,10) (Scheme 11-3). 
Dithionite reduction of the nitroso compounds 
(11.7,8) gave the diaminobipyrimidinones (11.11,12); 
the other nitroso compounds (11.9,10) gave the 
triaminobipyrimidines (11.13,14) (Scheme 11-4). 
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11-3 Preparation of 2-(Pyrimidin-4'-yl)purines 
The diaminobipyrimidinones (11.11,12) reacted with 
triethy1 orthoformate in acetic anhydride to give the 
purin-6-ones (11.15,16). These were converted by 
the 
phosphoryl chloride into Achloropurines (11.17,18) 
(Scheme 11-5). The chloropurine (Il.17) was then 
treated with thiourea to give the purine-6-thione 
(11.19) which underwent S-alkylation to give the 
thioethers (11.20,21). Treatment of the other 
ch10ropurine (11.18) with 2-dimethylaminoethylamine 
gave the dimethy1aminoethylaminopurine (11.22) 
(Scheme II-6). 
Fusion of the triaminopyrimidine (11.13) with 
thiourea at 2200 gave the purine-8-thione (Il.23) which 
underwent S-a1ky1ation to give the thioether (II.24). 
Acetylation of the thioether (11.24) with acetic 
36 
anhydride gave the diacetyl compound (Il.25) (Scheme II-7). 
The other triaminopyrimidine (11.14) was converted into 
the thione (Il.26) by boiling with carbon disulfide in 
pyridine and subsequent S-alky1ation gave the thioether 
(11.27) (Scheme 11-8). 
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11-4 Preparation of 2-(Pyrimidin-4'-yl)-pteridines and 
-quinazolines, and 5-(Pyrimidin-4'-yl)-lH= 
v-triazolo[4,5-d]pyrimidin-7(6H)-ones 
Condensation of the diaminobipyrimidinones (11.11,12) 
with glyoxal gave the pteridin-4-ones (11.28,29) or with 
nitrous acid gave the 5-(pyrimidin-4'-yl)-(lH)-v-triazolo -
[4,5-d]pyrimidin-7(6H)-ones (11.30,31) (Scheme 11-9). 
The pteridin-4-one (11.29) was converted by a mix ture of 
phosphoryl chloride and phosphorus pentachloride into 
the chloropteridine (11.32), and then by aminolysis to 
the dimethylaminoethylaminopteridine (11.33) (Scheme 
11-10) . 
Fusion of the amidine (11.3) with anthranilic acid 
(o-aminobenzoic acid) at 180 -1900 gave the quinazolin-
4-one (11.34) and subsequent thiation with phosphorus 
pentasulfide gave the quinazolinethione (11.35) 
(Scheme II-II). 
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11-5 Experimental 
(elemental) 
AnalysesAwere done by the Australian National 
University Analytical Services Unit. The n.m.r. spectra 
were measured at 90 MHz and 300 using tetramethylsilane 
or sodium 3-trimethylsilylpropane-l-sulfonate as internal 
standard in the indicated solvent and reporting chemical 
shifts in o. 
2-Dimethylaminopyrimidine-4-carboxamidiniurn Chloride (11.3) 
4,4-Dimethoxybutan-2-one and urea in ethanolic 
hydrochloric acid gave ll 4-methylpyrimidin-2(lH)-one 
hydrochloride (73 %) which was converted 8 by nitrous acid 
into 2-oxo-l,2-dihydropyrimidine-4-carboxaldehyde o x ime 
(63 %) and thence by treatment 8 with phosphoryl chloride 
into 2-chloropyrimidine-4-carbonitrile (11.1) (58 %), which 
in turn underwent dimethylaminolysis 7 to yield 2-
dimethylaminopyrimidine-4-carbonitrile (11.2) (66 %). 
This nitrile (14.8 g) and sodium methoxide (from 0.23 g 
of sodium) in methanol (100 ml) were stirred at 20-250 
for 2 h. Then solid ammonium chloride (6.30 g) was 
added and stirring was continued for 2 h. The solid was 
filtered off and washed with a little ether prior to 
recrystallization from ethanol to give the amidinium 
chloride (81 %), m.p. 285-2860 (Found: C, 42.0; H, 6.1; 
Cl, 17.9; N, 34.4. C7H12ClN5 requires C, 41.7; H, 6.0; 
Cl, 1 7 . 6; N, 34. 7 %) • 
2-Methoxypyrimidine-4-carboxamidinium Chloride (11.4) 
2-Chloropyrimidine-4-carbonitrile (11.1) 8 (13.95 g) 
was added over 20 min to a stirred solution of sodium 
methoxide (from 2.5 g of sodium) in methanol (100 ml) at 
00 and stirring was continued in the cold room for 12 h. 
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Then ammonium chloride (6.0 g) was added and stirring was 
maintained at 20-250 for 12 h. Salt was removed from 
the crude product during recrystallization from propan-2-ol 
to give the methoxyamidinium chloride (86%), m.p. 210 0 
(Found: C, 38.7; H, 4,7; Cl, 18.7; N, 29.6. C6H9ClN40 
requlres C, 38.2; H, 4 . 8 ; Cl, 18.8; N, 29.7%) . N.m.r. 
[(CD 3 ) 2S0 ] 9.77, s, br, 2NH2 ; 9.04, d, H 6; 7.98, d, H 5; 
4.06, s, Me. 
6-Amino-2'-dimethylamino-2,4'-bipyrimidin-4(3H)-one (11.5) 
The amidinium chloride (11.3) (2.0 g), ethyl 
cyanoacetate (1.15 g) and sodium ethoxide (from 0.5 g of 
sodium) in ethanol (20 ml) were heated under reflux for 
6 h and then evaporated under reduced pressure. Water 
(50 ml) was added to the residue and the resulting solid 
was filtered off: it proved to be ethyl 3-amino-2-cyano-
3-(2'-dimethylaminopyrimidin-4'-yl)acrylate (11.6) (43 %), 
m.p. 143-1450 (from ethanol) (Found: C, 55.3; H, 5.8; 
N, 26.6. C12H15N502 requires C, 55.2; H, 5.8; N, 26.8 %). 
o N.m.r. (CDC1 3 ; 25 ) 8.50, d, H 6'; 7.42, d, H 5'; 4.30, 
q, CH 2 of Et; 3.22, s, NMe 2 ; 1,36, t, Me of Et. The 
original aqueous filtrate was adjusted to pH 5 with 
WAS 
acetic acid and -the resulting solidArecrystallized from 
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ethanol to give the bipyrimidinone (11.5) (42 %), 
m.p. 305-306 0 (Found: C, 51. 7; H, 5. 3; N, 36. 5 . 
ClOH12N60 requires C, 51.7; H, 5.2; N, 36.2%). 
o N . m. r. (CDC1 3 ; 25 ) 8. 56, d, H 6'; 7. 24, d, H 5'; 
6 . 64, br, NH 2; 5 . 13, s, H 5; 3. 21 , s, NMe 2 . 
6-Amino-2'-dimethylamino-5-nitroso-2,4'-bipyrimidin-
4(3H)-one (11.7) 
(i) The foregoingbipyrimidinone (11.5) (2.32 g) 
ln 10 M hydrochloric acid (8.0 ml) was stirred at room 
temperature while sodium nitrite (2.1 g) was added little 
by little. The mixture was diluted with water (10 ml) 
and stirring was continued for 1 h. The solid was 
filtered off and washed with a little cold water: the 
nitrosobipyrimidinone (73 %) had m.p. 273 0 (dec.) (from 
ethanol) (Found: C, 46.3; H, 4 . 3 ; N, 37.8. ClOHllN702 
requlres C, 45.9; H, 4 . 2 ; N, 37.5 %). N.m.r. [ (CD3 ) 2S0 ; 25
0 ] 
9.33, br, NH2 ; 8.64, d, H 6'; 7.29, d, H 5'; 3.25, s, NMe 2 · 
(ii) 2-Dimethylaminopyrimidine-4-carboxamidinium 
hydrochloride (11.3) (2.01 g), ethyl 2-cyano-2-
hydroxyiminoacetate 9 (1.44 g) and sodium ethoxide (from 
0.90 g of sodium) in ethanol (20 ml) were boiled under 
reflux for 20 h. After refrigeration, the solid was 
filtered off and washed with cold ethanol. It was then 
suspended in water (20 ml) and acidified to pH 5 by the 
addition of acetic acid to give the same nitrosobipyrimidinone 
(77 %) as in (i) above. 
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6-Amino-2'-methoxy-S-nitroso-2,4'-bipyrimidin-4(3H)-
one (11.8) 
The above amidinium chloride (1.90 g), ethyl 2-cyano-
2-hydroxyiminoacetate 9 (1.45 g) and sodium methoxide 
(from 0.95 g of sodium) in methanol (20 ml) were 
stirred at 200 for 15 h. The solid was treated as 
for the analogue (11.7) above to give the 
methoxynitroso derivative (82%), m.p. >240 0 (dec.) 
(from methoxyethanol)( Found: C, 43.9; H, 3.4; N, 33. 7 . 
C9H8N60 3 requires C, 43.6; H, 3.2; N, 33.9%). 
2'-Dimethylamino-S-nitroso-2,4'-bipyrimidine-4,6-diamine 
(11.9) 
The silver salt of a-hydroxyiminomalononitrile 10 
(2.2 g) was added little by little to a stirred solution 
of 2-dimethylaminopyrimidine-4-carboxamidinium chloride 
(11.3) (2.0 g) in methanol (100 ml) at room temperature. 
After stirring for a further 60 min, silver chloride was 
filtered off and the filtrate was evaporated to dryness 
at 20-250 under reduced pressure. The residual salt was 
boiled under reflux in 2-methy/pyridine (15 ml) for 15 min and 
the cooled reaction mixture was diluted with ice - water. 
Refrigeration gave the dimethylaminobipyrimidine (11.9) 
o (84 %), m.p. 324-326 (from 2-methoxyethanol) (Found: 
C, 46.3; H, 4.4; N, 43.2. CIOH12N80 requires C, 46.2; 
H, 4.6; N, 43.1 %). N.m.r. [(CD3)2S0] 8.50, d, H 6'; 
7 . 2 2, d , H 5' i 3. 18, s, NMe 2 . 
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2'-Methoxy-5-nitroso-2,4'-bipyrimidine-4,6-diamine (11.10) 
In a similar way, 2-methoxypyrimidine-4-
carboxamidinium chloride (11.4) (1.9 g) gave the 
hygroscopic methoxybipyrimidine (78 %), m.p. 289 0 (dec.) 
( F 0 un d : C , 3 9 . 5; H, 4. 0; N, 3 5 . 4 . C9H9N7 02 ·1.5 H2 0 
requlres C, 39. 4; H, 4.4; N, 35. 7 %) . N.m.r. 
[ (CD3 ) 2 SO] 8. 80, d, H 6'; 7. 82, d, H 5'; 3. 98, s, OMe. 
5,6-Diamino-2'-dimethylamino-2,4'-bipyrimidin-4(3H)-one 
(11.11) 
The nitroso compound (11.7) (13.05 g) was stirred 
in 1 M sodium hydroxide (200 ml) at 600 while sodium 
dithionite (c. 15-20 g) was added until the suspension 
became a s olution and no further colour change occurred. 
The solution was boiled gently for 10 min, and then 
neutralized with acetic acid and cooled to 150 to 
complete precipitation of the diaminobipyrimidinone (82 %), 
o 
m.p. >220 (dec.) (from aqueous methanol) (Found: C, 
43.5; H, 5.5; N, 39.4. CIOH13N70 requires C, 43.6; 
H, 5.3; N, 39.6%). N . m. r. [( CD 3) 2 SO] 8. 52, d, H 6'; 
7 . 2 2, d, H 5'; 6 . 7 0, s, NH 2; 5. 91 , s, NH 2; 3. 2 2, s, NMe 2 . 
5,6-Diamino-2'-methoxy-2,4'-bipyrimidin-4(3H)-one (11.12) 
The nitroso compound (11.8) (12.4 g) was reduced 
exactly as for analogue (11.11) above. The crude 
product was purified by dissolution in hot aqueous 
ammonla and reprecipitation with acetic acid followed 
by appropriate washing. The diamine (80 %) had m.p. >264 0 
.-' 
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(dec. ) ( F 0 un d : C , 4 5 . 9; H , 4. 3; N, 3 5 . 7 . C 9 H ION 6 0 2 
requires C, 46. 2; H, 4. 3; N, 35. 9 %) . 
2'-Dimethylamino-2,4'-bipyrimidine-4,5,6-triamine (11.13) 
The nitroso derivative (11.9) (1.0 g), sodium 
dithionite (4.0 g) and 1 M sodium hydroxide (40 ml) were 
heated under reflux for 1 h. Chilling gave the 
dimethylaminotriamine (82%), m.p. 269-2700 (from ethanol) 
(Found: C, 48.4; H, 5.9; N, 45.5. ClOH14N8 requires 
C, 48.8; H, 5.7; N, 45.5%). N.m.r. [(CD3)2S0] 8.32, d, 
H 6'; 7. 2 2, d , H 5'; 5. 7 4, s, 4 + 6 - NH 2; 4. 2 3, s, 5 - NH 2 ; 
3.46, s, NMe 2 . 
2'-Methoxy-2,4'-bipyrimidine-4,5,6-triamine (11.14) 
The nitroso compound (11.10) was reduced similarly, 
but in pyridine (40 ml) with heating for 6 h. The cooled 
solution was filtered from inorganic matter and subsequent 
evaporation under reduced pressure gave the methoxytriamine 
o (85%), m.p. 232-233 (from ethanol) (Found: C, 46. 4 ; 
H, 4.9; N, 42.0. C9HllN7 0 requires C, 46.3; H, 4 . 8 ; 
N, 42.0%). N.m.r. [(CD3 )2 S0 ] 8.56, d, H 6'; 7 . 73, d, 
H 5'; 5.81, s, 4 + 6-NH 2 ; 4 . 36, s, 5-NH 2 ; 3.94, s, OMe. 
2-(2'-Dimethylaminopyrimidin-4'-yl)purin-6(lH)-one (11.15) 
The diamine (11.11) (2.47 g), triethyl orthoformate 
(18.0 ml) and acetic anhydride (12.5 ml) were boiled under 
reflux for 15 min and then evaporated to dryness. 
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Recrystallization of the residue from a large volume of 
chloroform with subsequent concentration gave the purinone 
(93%), m.p. 3480 (dec.) ( Found: C , 51. 5; H , 4. 3; N, 
38.0. ell H"N7 0 requires C, 51.4; H, 4.3; N, 38.1 %). 
2-(2'-Methoxypyrimidin-4'-yl)purin-6(lH)-one (11.16) 
The diamine (11.12) (2. 34 g) was converted, as for 
the analogue (11.15) into the methoxypyrimidinylpurinone 
o (85%), m.p. >308 (dec.) (from methoxyethanol) (Found: 
C, 49.3; H, 3.2; N, 34.5. C10H8N602 requires C, 49.2; 
H, 3.3; N, 34.4%). N.m.r. [(CD3 ) 2S0] 8.85, d, H 6'; 8.28, 
s, H 8; 7. 9 3, d , H 5'; 4. 11, s , Me. 
6-Chloro-2-(2'-dimethylaminopyrimidin-4'-yl)purine 
(11.17) 
The purinone (11.15) (2.57 g) and phosphoryl chloride 
(25 ml) were heated under reflux for 2 h. The excess of 
phosphoryl chloride was removed under reduced pressure and 
the r esidue was stirred thoroughly with crushed ice. The solution 
was adjusted to pH 5 at 0-50 . The solid was filtered 
off and washed with a little water prior to drying in a 
vacuum; subsequent recrystallization from methoxyethanol 
gave the chloropurine (58%), m.p. 204 0 (Found: C, 4 7 . 7 ; 
H, 3.8; Cl, 12.7; N, 35.4. CllH10C1N7 requires C, 47.9; 
H, 3. 7; Cl, 12. 9; N, 35. 6 %) . N.m.r. [(CD3 )2 S0 ] 8.77, s, 
H 8; 8. 54, d, H 6; 7. 4 7, d, H 5; 3. 23, s, NMe 2 . 
6-Chloro-2-(2'-methoxypyrimidin-4'-yl)purine (11.18) 
The above purinone (11.16) (2.44 g) was treated with 
phosphoryl chloride as for the analogue (11.17) to give 
the chloropurine (63%), m.p. >3600 (from glacial acetic 
acid) (Found: C, 45.7; H, 2.9; N, 32.0. ClOH7ClN 6 0 
requires C, 45.7; H, 2.7; N, 32.0%). 
2-(2'-Dimethylaminopyrimidin-4'-yl)purine-6(lH)-thione 
(11.19) 
The chloropurine (11.17) (2.76 g), thiourea (1.0 g) 
and ethanol (25 ml) were boiled under reflux for 30 min. 
After refrigeration, the solid was recrystallized from 
methoxyethanol to give the purinethione (83%), m.p. >325 0 
(dec. ) (Found: C, 48.2; H, 4. 2; N, 35. 8; S, 11.9. 
CllHllN7S requires C, 48.3; H, 4.1; N, 35.9; S, 11.7%). 
N,N-Dimethyl-4-(6'-methylthiopurin-2'-yl)pyrimidin-2-
amine (11.20) 
The pyrimidinethione (11.19) (2.73 g) was dissolved 
In 2 M sodium hydroxide (20 ml) and the solution was' 
shaken with methyl iodide (2.0 g) for 2 h at 20-250 . 
The chilled mixture was adjusted to pH 5 with acetic acid 
and the product was filtered off. The methylthiopurine 
o (74%) had m.p. 307 (from methoxyethanol) (Found: C, 
49.9; H, 4.4; N, 33.7; S, 11.0. C12H13N7S requires 
C, 50.2; H, 4.6; N, 34.1; S, 11.2%). 
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2- [2' - (2" -Dimethylaminopyrimidin-4" -yl) purine-6'-yl thio]-
N,N-dimethylethylamine (11.21) 
A solution of the purinethione (11.19) (2.73 g) In 
2 M sodium hydroxide (20 ml) was stirred while 2-chloro-
N,N-dimethylethylammonium chloride (1.70 g) was added over 
10 min. After stirring for a further 2 h, the mixture 
was extracted with chloroform (3 x 40 ml) . The 
dehydrated extract was evaporated to give the purinylthio-
ethylamine (57 %) , m.p. 206-2070 (from ethyl acetate) 
(Found: C, 52.2; H, 5.7; N, 32.1; S, 9.4. C15H20N8S 
requlres C, 52.3; H, 5.8; N, 32.5; S, 9.3 %) . N.m.r. 
o (CDC1 3 ; 25 ) 8. 59, d, H 6"; 8. 02, s, H 8'; 7. 72, d, H 5"; 
3 . 6 4, t , H 2; 3. 2 8, s , 2" - NMe 2; 2. 7 8, t, H 1; 2. 3 8, s, 
l-NMe 2 · 
N-(2"-Dimethylaminoethyl)-2-(2'-methoxypyrimidin-4'-y1)-
purin-6- a mine (11.22) 
The chloropur ine ( 11. 18) (1 . 0 g) and 2 -dimethy lamino-
ethylamine (5.0 ml) were boiled under reflux for 1 h. 
The residue, from removal of the excess of amine under 
reduced pressure, was added to 2 M sodium hydroxide (5.0 ml) 
and extracted with chloroform. Evaporation of the dried 
extract gave the purinamine (42%), m.p. 185-1860 (from 
propan-2-ol) (Found: C, 53. 8; H, 5. 8; N, 35. 7 . 
C14H18N80 requires C, 53.5; H, 5.8; N, 35.6 %). 
6-Amino-2-(2'-dimethylaminopyrimidin-4'-yl)purine-8(7H)-
thione (11.23) 
The triamine (11.13) (1.0 g) and thiourea (1.20 g) 
o 
were ground together and then fused at 220 for 1 h. 
A solution of the cooled mixture in 2 M sodium hydroxide 
was decolourized with carbon and acidified with 
hydrochloric acid to give the purinethione (68%), m.p. 
251 0 (dec.) (from glacial acetic acid) (Found: C, 45. 9 ; 
H, 4.3; N, 38.7; S, 10.8. CIIH12N8S requires C, 45.8; 
H, 4 . 2 ; N, 38.9; S, 11.1%) . N.m.r. [(CD 3 )2 S0 ] 8.53, d, 
H 6'; 7.36, d, H 5'; 3.28, s, NMe 2 · 
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8-(2"-Dimethylaminoethyl)thio-2-(2'-dimethylaminopyrimidin-
4'-yl)purin-6-amine (11.24) 
2-Chloro-N,N-dimethylethylamine hydrochloride (0.8 g) 
was added over 10 min to a stirred solution of the 
purinethione (11.23) (1.0 g) in 2 M sodium hydroxide 
(20 ml) at room temperature. Stirring was continued for 
a further 2 h and the alkaline solution was then adjusted 
to pH 8 with hydrochloric acid. Extraction with 
chloroform, dehydration of the extract, and evaporation thereof 
gave the purinamine (11.24) (61%), m.p. 236 0 (from ethyl 
acetate) (Found: C, 49. 9; H, 6. 0; N. 35. 0 . 
requlres C, 50.1; H, 5.9; N, 35.1%). N.m.r. 
C15H21N9S 
(CDC1 3 ) 
8 . 4 6, d , H 6'; 7. 4 8, d, H 5'; 5. 5 9, b r, NH 2; 3. 2 9, s, 
2 ' - NMe 2 i 3. 11, t , H 1" i 2. 87, t , H 2 "; 2. 4 5, s, 2 II - NMe 2 . 
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N-[9-Acetyl-8-(2"-dimethylaminoethyl)thio-2-(2'-
dimethylaminopyrimidin-4'-yl)purin-6-yl]acetamide (11.25) 
The purinamine (11.24) (0.3 g) and acetic anhydride 
(5.0 ml) were heated under reflux for 5 h. The excess 
of anhydride was distilled off under reduced pressure to 
leave the diacetyl derivative (11.25) (62%), m.p. 216 0 
(from ethanol) (Found: C, 51.1; H, 5.8; N, 28.5; 
C19H35N902S requires C, 51.4; H, 5.7; N, 28.4 %). N.m.r. 
(CDC1 3 ) 8. 50, d, H 6'; 8. 36, br, NH; 7. 45, d, H 5'; 3. 44 , 
t, HI"; 3. 29, s, 2' - NMe 2; 3. 15, s, 9 - Ac; 2. 89, s, Me 0 f 
NHAc ; 2. 74, t, H 2"; 2. 33, 3, 2" - NMe 2 . 
6-Amino-2-(2'-methoxypyrimidin-4'-yl)purine-8(7H)-
thione (11.26) 
The triamine (11.14) (1.0 g), carbon disulfide (1.5 g), 
solid sodium hydroxide (0.20 g) and pyridine (20 ml) were 
heated under reflux for 1 h. The cooled mixture was 
diluted with 1.25 M hydrochloric acid. The resulting 
solid was decolourized as above to give the thione 
(11.26) (71 %), m.p. 230 0 (dec.) . (from glacial acetic 
acid) (Found: C, 43.9; H, 3.4; N, 35.3. CIO H9N70S 
requlres C, 43. 6; H, 3. 3; N, 35. 6 %) . N.m.r. [(CD3 ) 2S0 ] 
8 . 72, d, H 6'; 7. 83, d, H 5'; 7. 42, br, NH 2; 3. 98, s, 
OMe. 
8-(2"-Dimethylaminoethyl)thio-2-(2'-methoxypyrimidin-
4'-yl)purin-6-amine (11.27) 
In a similar way to (11.24), apart from stirring at 
60 0 for only 30 min, the purinethione (11.26) was 
converted into the purinamine (54%), m.p. 2130 (from 
ethanol) (Found: C, 48.4; H, 5.2; N, 32.2. 
requlres C, 48. 5; H, 5. 2; N, 32. 4 %). N . m. r. 
C14H18N80S 
[(CD 3 )2 S0 ] 
8.69, d, H 6'; 7.88, d, H 5'; 7.00, br, NH 2 ; 3.99, s, 
OMe; 3. 43, t, H 2"; 2. 68 , t I H 2"; 2. 25 , s I NMe 2 . 
2-(2'-Dimethylaminopyrimidin-4'-yl)pteridin-4(3H)-one 
(11.28) 
The diamine (11.11) (2.47 g) I aqueous glyoxal (40%; 
1.5 ml) and ethanol (20 ml) were heated under reflux for 
30 min. Refrigeration gave the pteridinone (76%) I m.p. 
266-267 0 (from dimethylformamide) (Found: C, 53.6; 
H, 4.1; N, 36.4. C12HllN70 requires C, 53.5; H, 4.1; 
N I 36. 4 %) . N . m. r. (CDC1 3 ) 9. 02 , d I H 6; 8. 88 , d I H 7; 
8 . 6 3, d , H 6'; 7. 7 5 I d I H 5'; 3. 3 0 I S I NMe 2 . 
2-(2'-Methoxypyrimidin-4'-yl)pteridin-4(3H)-one 
(11.29) 
The diamine (11.12) (2.34 g) I aqueous glyoxal 
(40%; 2.0 ml) and water (20 ml) were warmed on the water 
bath for 15 min. Refrigeration gave the pteridinone 
(92%) I m.p. >278 0 (dec.) (from dimethylformamide) 
56 
(Found: C, 51.4; H, 3.1; N, 32.7. CIIH8N602 
requires C, 51.6; H, 3.1; N, 32.8 %). N.m.r. 
[ (CD3 ) 2 SO] 9. 08, d, H 6; 8. 93, d, H 7; 8. 92, d, H 6'; 
8 . 0 5, d , H 5'; 4. 14, s, Me. 
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5-(2'-Dimethylaminopyrimidin-4'-yl)-(lH)-v-triazolo[4,5-d]-
pyrimidin-7(6H)-one (11.30) 
Sodium nitrite (0.5 g) was added over 10 min to a 
stirred solution of 5,6-diamino-2'-dimethylamino-2,4'-
bipyrimidin-4(3H)-one (11.11) (1.0 g) in 2 M hydrochloric 
acid (10 ml) at 00 . stirring was continued at 00 for 
30 min and then at 25 0 for 2 h, after which the 
triazolopyrimidinone (11.30) 
and washed with iced water. 
(Found: C, 46.8; H, 4 . 3 ; N, 
C, 46.5; H, 3 . 9 ; N, 43.4 %) . 
d, H 6'· , 7.26, d, H 5'; 3.14, 
(63 %) was filtered off 
o It has m.p. 304 
43.3. CIOHION80 requlres 
N.m.r. (NaOD/D 2 0) 8 . 34, 
s, NMe 2 · 
5-(2'-Methoxypyrimidin-4'-yl)-(lHl=v-triazolo[4,5-d]-
pyrimidin-7(6H)-one (11.31) 
In a similar way, 5,6-diamino-2'-methoxy-2,4'-
bipyrimidin-4(3H)-one (11.12) gave the triazolopyrimidinone 
o (11.31) (54 %), m.p. 308 (dec.) (Found: C, 44.3; H, 2.9; 
N, 39.6. C9H7N70 requires C, 44.1; H, 2.9; N, 40.0 %). 
N.m.r. (NaOD/D2 0) 8.52, d, H 6'; 7.75, d, H 5'; 4.01, s, 
OMe. 
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4-Chloro-2-(2 1 -methoxypyrimidin-4 1 -yl)pteridine (11.32) 
The pteridinone (11.29) (1.0 g), phosphoryl chloride 
(50 ml) and phosphorus pentachloride (1.0 g) were boiled 
under reflux for 4 h. The phosphoryl chloride was 
distilled off under reduced pressure and the residue 
was stirred into crushed ice and allowed to stand at 
o 5 for 15 h. Filtration gave the chloropteridine 
o (11.32) (72%), m.p. 232-233 (from methanol) (Found: 
C, 47.8; H, 2.6; Cl, 12.5; N, 30.6. 
C, 48.1; H, 2.6; Cl, 12.9; N, 30.6%). 
CIIH7CIN 6 0 requires 
N.m.r. [(CD3)2S0] 
9.06, d, H 6; 8.92, d, H 7; 8.90, d, H 6 1 ; 8.05, d, 
H 5 I; 4. 14, s, Me. 
N-(2"-Dimethylaminoethyl)-2-(2 1 -methoxypyrimidin-4 1 -y1)-
pteridin-4-amine (11.33) 
The foregoing chloropteridine (1.0 g) and 2-
dimethylaminoethylamine (6.0 ml) were heated under reflux 
for 1 h. The residue from distilling off the excess of 
amlne under reduced pressure was diluted with 2 M sodium 
hydroxide and the mixture was extracted with chloroform. 
Evaporation of the extract gave the pteridinamine (34%), 
o 
m.p. 158-159 (from propan-2-o1) (Found: C, 54.9; H, 
5.6; N, 34.0. C15H18N80 requires C, 55.2; H, 5.6; 
N,34.3%). N . m. r. (CDC1 3 ) 9. 06, d, H 6; 8. 72, d, H 7; 
8 . 70, d, H 6 I; 8. 18, d, H 5 I; 7. 82, br, NH; 4. 16, s, 
OMe ; 3. 90, q, H I"; 2. 67, t, H 2 "; 2. 1 7, s, NMe 2 . 
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2-(2 '-Dimethylaminopyrimidin-4 '-yl)quinazolin-4 (3H)-one 
(11.34) 
2-Dimethylaminopyrimidine-4-carboxamidiniurn chloride 
(11.3) (1.5 g) and anthranilic acid (0.5 g) were fused 
o together at 180 for 1 h. The cooled mixture was 
triturated with a little water and filtration gave the 
quinazolinone (62%), m.p. 248 0 (from ethanol) (Found: 
C, 62.3; H, 4.8; N, 25.8. C14H13N50 requires C, 62.9; 
H, 4.9; N, 26.2%). N.m.r. (NaOD/D2 0) 8.29, d, H 6'; 
7 . 6 9, m, H 5 - 8; 7. 18, d , H 5'; 3. 11, s, N~e 2 . 
2-(2'-Dimethylaminopyrimidin-4'-yl)quinazolin-4(3H)-thione 
(11.35) 
The quinazolinone (11.34) (0.5 g), phosphorus 
pentasulfide (0.6 g) and pyridine (30 ml) were heated 
under reflux for 2 h. The cooled mixture was poured 
into ice water (150 ml) and refrigeration gave the 
quinazolinethione (57 %), m.p. 232 0 (from ethanol) 
(Found: C, 59.0; H, 4 , 6 ; N, 24 .4. C14H13N5S requlres 
C, 59.3; H, 4 . 6 ; N, 24.7%). N.m.r. (CDC1 3 ) 8.78 , d, 
H 6'; 8.58, d, H 5 ' ; 7 . 73, m, H 5-8; 3.32, s, NMe 2 · 
60 
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111-1 
CHAPTER III 
SYNTHESIS OF SOME PHENYLPURINES, 
PHENYLPTERIDINES, AND 
PHENYLQUINAZOLINES 
Introduction 
Unfused heterobicycles, such as N,N-dimethyl-2-
[6'-methyl-2'-(pyridin-4"-yl)pyrimidin-4'-ylthio]-
ethy1amine (III.la), N,N-dimethyl-2-[5'-pyridin-4"-yl)-
l' ,3' ,4 '-thiadiazol-2 '-ylthio] ethyl amine (III.lb), and 
in particular N,N-dimethyl-2-(6'-methyl-2'-phenyl-
pyrimidin-4'-ylthio)ethylamine (111.2) (Scheme 111-1) 
have been reported elsewhere as having high activities 
as amplifiers of phleomycins against E. coli in vitro 
61 
and also (for two of the above) against tumors in vivo}-4 
In view of the fact that fused heterobicycles such 
as purines have also shown quite high activity, it 
seemed worthwhile to prepare appropriate phenylpurines, 
phenylpteridines and phenylquinazolines. In effect, 
these systems amount to the annelation of an imidazole, 
pyrazine and benzene ring to the pyrimidine ring of the 
above-mentioned highly active phenylpyrimidines. 
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111-2 Preparation of Phenylpurine Derivatives 
Aminolysis of 6-chloro-2-phenylpurine (111.3) 5 with 
2-dimethylaminoethylamine gave the aminopurine (111.4), 
and S-alkylation of the purine-6-thione (111.5) 6 gave 
the thioether (III. 6) (Scheme III -2) . Fusion of the 
triaminopyrimidine (111.7) 7 with thiourea gave the 
purine-8-thione (111.8) which underwent S-alkylation by 
2-chloro-N,N-dimethylethylamine to give the thioether 
(I I I. 9) (Scheme I I 1-3) ~ Methylation of the pyrimidine-
2-thione (111.10) 8 with methyl iodide gave the 
methylthiopyrimidine (111.11) which underwent condensation 
with dimethoxyrnethyl acetate to give the 2-methylthiopurine 
(111.12) (Scheme 111-4). 
Dithionite reduction of nitroso compound UIT.14), 
which was prepared by condensation of the pyridine-4-
carboxamidinium chloride (111.13) 9 with ethyl 2-cyano-
2-hydroxyiminoacetate gave the pyrimidinediamine (111.15) 
(Scheme 111-5). This was converted by triethyl 
orthoformate in acetic anhydride into the pyridinyl-
hypoxanthine, (111.16) and thence by phosphorus pentasulfide 
into the purine-6-thione (111.17) which underwent 
S-alkylation to give the thioether (111.18). 
S-Alkylation of 8-phenylpurine-6-thione (111.19) 10 
with 2-chloro-N,N-dimethylethylamine gave the thioether 
(111.20) (Scheme 111-6). 2-Chloro-8-phenylpurine (111.25) 
oxidative 
was prepared by two methods: (i) ",cyclization (with NBS) of 1he 
5-benzylideneamino-2-chloropyrimidine (Ill.22), which was 
obtained by the reaction of 2-chloropyrimidine-4,5-
diamine (111.2U11 with benzaldehyde; (ii) cyclization and 
(111.3) 
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chlorination of the 5-benzamidopyrimidin-2-one (111.24) 
which was obtained by the reaction of 4,5-diamino-
pyrimidin-2-one (111.23) 12 with benzoyl chloride. 
(Scheme 111-7). This chloro compound (111.25) was 
' 1 then converted by thiourea into the purine-2-thione 
(111.26).13 
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III-3 Preparation of Phenylpteridine Derivatives 
Aminolysis of 6-chloro-5-nitro-2-phenylpyrimidin-
4-amine (III.27) 14 with 2-dimethylaminoethylamine gave 
the aminopyrimidine (III.28). This was converted by 
reduction with dithionite into the pyrimidine-4,5-
diamine (III.29) and subsequent condensation with 
glyoxal and diacetyl gave the pteridines (III.30,3l) 
(Scheme III-8). Methylation of the pteridine-4-thiones 
(III.33,34), obtained by condensation of the pyrimidine-
4-thione (III.32) 14 with glyoxal and diacetyl, gave the 
4-methylthiopteridines (III.35,36) (Scheme III-9). 
, 
Condensation of the 2-chloropyrimidine (III.37) 11 and 
2-methylthiopyrimidine (III.ll) with glyoxal and 
diacetyl gave the 2-chloropteridine (III.38) and the 
2-methylthiopteridines (III.39,40) (Scheme III-10). 
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CI 
N02 
NH2 
(111.27) 
HNCH2CH2NMe2 
N02 
~ 
P""" 
NH2 
(III.28} 
(Scheme 111-8) 
HNCH2CH2NMe2 
NH2 
NH2 
(111.29) 
~ 
HNCH2CH2NMe2 
N~R 
~R N 
(111.30 ; R = H) 
(111.31 ; R = Me) 
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rh Ph 
N/" ~NH2 N)=R2 
1 " I ~ ; R2 R~N NH2 
I ~1 N 
Rl R 2 
(111.37; R1= Cl) (111.38) Cl Me 
( 111 . 11 ; R1 = SMe) (111.39) SMe H 
(111.40) SMe Me 
(Scheme 111-10) 
i 
III 
I, 
III 
f 
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111-4 Preparation of Pheny1quinazo1ine Derivatives 
I 
Aminolysis of 4-ch1oro-2-phenyl- (111.41) 15 and 
2-ch1oro-4-phenyl-quinazo1ine (111.42) 16 with 
2-dimethy1aminoethy1amine gave the quinazo1inamines 
( I I I . 43) 1 7 and ( I I I . 44) (Scheme III-II). S-A1ky1ation 
75 
of 2-pheny1quinazo1ine-4(3H)-thione (111.45) 18 and the positio~ai 
isomer (111.48) 19 gave the thioethers (111.46,47,49,50) 
(Scheme 111-12). Fusion of the amidine (111.13) 9 with 
anthranilic acid gave the quinazo1in-4-one (111.51) .20 
This was converted successively into the thione (111.52) 
and the thioether (111.53) 
a\ ky l £l,ti on . 
(Scheme I I I -13) by th ia tjon amcL 
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II (111.41) Ph Cl (111.43) Ph NHCH2CH2NMe2 
, I (111.42) Cl Ph (111.44) NHCH 2CH 2NMe 2 Ph 
I I 
! I 
I 
I 
. (Scheme III-II) 
~ 
i I' 
I , 
I I 
I 
I 
I 
I 
I '
I 
I" 
I I 
I , 
I I I 
I ' 
f~ " 
I 
m 
: I 
IL 
I 
I I I, 
I I 
77 
SR 
HN 
Ph~ N 
______ ........ 1'1/ 
Phh N 
(111.45) (111.46 ; R = CH 2CH 2NMe 2 ) 
(111.47 ; R = CH 2CH 2CH 2NMe 2 ) 
Ph Ph 
(111.48) (111.49 ; R = CH 2CH 2NMe 2 ) 
(111.50 ; R = CH 2CH 2CH 2NMe 2 ) 
(Scheme 111-12) 
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111-5 Experimental 
Analyses were done by the Australian National 
University Analytical Services Unit. The n.m.r. spectra 
were measured at 90 MHz and 300 using tetrqmethylsilane or 
sodium 3-trimethylsilylpropane-l-sulfonate as internal 
standard in the indicated solvent and reporting chemical 
shI'tts in o. 
N-(2'-Dimethylaminoethyl)~2-phenylpurin-6-alnine (111.4) 
6-Chloro-2-phenylpurine 5 (111.3) (1. 0 g) and 
2-dimethylethylamine (5.0 g) were boiled under reflux for 
2 h. The excess of amine was recovered by distillation 
and the residue was diluted with water (10 ml), a~justed 
to pH 11.0, and then extracted with ether. Evaporation 
of the extract gave the purinamine (111.4) (57%), 
o 
m.p. 214 (from ethanol) (Found: C, 60.0; H, 6.3; N, 
28.1 C15H18N6·H20 requires C, 60.0; H, 6.7; N, 28.0%). 
N.m.r. (CDC1 3 ) 8.17, m, Ph; 8.00, s, H 8; 7.38, m, Ph; 
3 . 97, g, HI'; 3. 02, t, H 2'; 2. 63, s, NMe 2 . 
N,N-Dimethyl-2-(2'-phenylpurin-6'-ylthio)ethylamine (111.6) 
2-Chloro-N,N-dimethylethylamine hydrochloride (0.80 g) 
was added during 10 min to a stirred solution of 
2-phenylpurine-6 (lH) -thione 6 (111.5) (1.00 g) in 2 M 
sodium hydroxide (20 ml) at 25°. Stirring was continued 
for 2 h. and then the solution was adjusted to pH 8 with 
hydrochloric acid. Extraction with chloroform, 
dehydration of the extract, and subsequent evaporation 
~I 
~ . 
1111 
I' 
,'I 
'I 
, 
J 
I, 
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gave the purinylthioethylamine (111.6) (73%), m.p. 163-1650 
(from ethyl acetate) (Found: C, 60.1; H, 5.6; N, 23.0. 
C15H17N5S requires C, 60.2; H, 5.7; N, 23.4%). 
N.m.r. (CDC1 3 ) 8.35, m, Ph; 8.05, s, H 8'; 7.41, m, Ph; 
3 . 68, t , H 2; 2. 9 0, t, HI; 2. 4 3, s, NMe 2 . 
6-Arnino-2-phenylpurine-8(7H)-thione (111.8) 
2-Phenylpyrimidine-4,5,6-triamine 7 (111.7) (1.0 g) and 
thiourea (1.0 g) were ground together and then fused at 
o 220 for 1 h. A solution of the cooled mixture in 2 M 
sodium hydroxide was decolourized with carbon and then 
adjusted to pH 5-6 with hydrochloric acid to give the 
thione (111.8) o (92%), m.p. 282 (from ethanol) 
(Found: C, 54.4; H, 3.7; N, 28.6. CllH9N5S requires 
C, 54.3; H, 3.7; N, 28.8%). N.m.r. (1 M NaOD) 8.00, m, 
Ph; 7.51, m, Ph. 
8-(2'-Dimethylaminoethylthio)-2-phenylpurin-6-amine (111.9) 
A solution of the above purinethione (111.8) (1.0 g) 
In 2 M sodium hydroxide (20 ml) was stirred while 2-chloro-
N,N-dimethylethylammonium chloride (0.7 g) was added over 
10 min. After stirring for a further 2 h, the mixture 
was extracted with chloroform. The dehydrated extract 
,was evaporated to give the purinamine (111.9) (68%), 
o 
m.p. 215 (from ethanol) (Found: C, 57.7; H, 5.8; N, 26.7. 
C15H18N6S requires C, 57.3; H, 5.8; N, 26.7%). N.m.r. 
[(CD3)2S0] 8.31, m, Ph; 7.43, m, Ph; 6.98, s, br, NH 2 , 
3 . 41, t, HI'; 2. 60, t, H 2', 2. 21, s, NMe 2 . 
....... 
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2-Methylthio-6-phenylpyrimidine-4,5-diamine (111.11) 
4,5-Diamino-6-phenylpyrimidine-2(lH)-thione 8 (111.10) 
(1.0 g), 1 M sodium hydroxide (20 ml) and methyl iodide 
(1.0 ml) were stirred at 25 0 for 2 h. Filtration gave 
the methylthiopyrimidine (111.11) (69%), m.p. 2110 (from 
ethanol) (Found: C, 56.7; H, 5.2; N, 24.0. CllH12N4S 
requlres C, 56.9; H, 5.2; N, 24.1%). 
2-Methylthio-6-phenylpurine (111.12) 
The above methylthiopyrimidine (111.11) (0.50 g) and 
dimethoxymethyl acetate (10 ml) were boiled under reflux 
for 3 h. 
(111.12) 
Evaporation in a vacuum gave the methylthiopurine 
o (63%), m.p. 258 (from ethanol) (Found: C, 59.6; 
H, 4.2; N, 23.0. C12Hl0N4S requires C, 59.5; H, 4.2; N, 
23.1%). N.m.r. [(CD3)2S0] 8.79, m, Ph; 8.50, s, H 8; 2.64, 
s, Me. 
5,6-Diamino-2-(pyridin-4'-yl)pyrimidin-4(3H)-one (111.15) 
pyr idine-4 -carboxamidini urn chlor ide 9 (I I I. 13) ( 3 .16 g), 
ethyl 2-cyano-2-hydroxyiminoacetate (2.88 g) and ethanolic 
sodium ethoxide (sodium: 1.84 gi ethanol: 40 ml) were 
boiled under reflux for 20 h. Refrigeration gave crude 
6-amino-5-nitroso-2-(pyridin-4'-yl)pyrimidine-4(3H)-one 
(111.14) as sodium salt, which was filtered off, washed 
with cold ethanol, and then stirred in water (80 ml) at 
600 while sodium dithionite was added until the mixture 
became a clear solution and no further colour change 
occurred. After boiling for 10 min, the solution was 
cooled to give the diaminopyrimidinone (111.15) (64%), 
o 
m.p. >292 (dec.) (from methoxyethanol) (Found: C, 
53.0; H, 4.4; N, 34.3. C9H9N50 requires C, 53.2; H, 
4.5; N, 34.5%). 
2-(Pyridin-4'-yl)purin-6(lH)-one (111.16) 
The diaminopyrimidinone (111.15) (2.03 g), triethyl 
orthoformate (18.0 ml) and acetic anhydride (12.5 ml) 
were boiled under reflux £or 15 min. The residue from 
evaporation in a vacuum was triturated with water and the 
solid was removed and washed with ether to give the 
purinone (111.16) (70%) m.p. >3600 (from methoxyethanol) 
(Found: C, 56.5; H, 3.3; N, 33.0. ClOH7N5 0 requires 
C, 56.3; H, 3.3; N, 32.9%). N.m.r. (NaOD/D2 0) 8.58, d, 
H 2',6'; 8.03, d, H 3',5'; 7.94, s, H 8. 
N,N-Dimethyl-2-[2'-(pyridin-4"-yl)purin-6'-ylthio]-
ethylamine (111.18) 
The above purinone (111.16) (1.0 g), phosphorus 
pentasulfide (4.0 g) and pyridine (40 ml) were boiled 
under reflux for 4 h. The residue from removal of the 
82 
solvent under reduced pressure was dissolved in 2 M sodium 
hydroxide (40 ml) and then reprecipitated by acidification 
with acetic acid. The crude pyridinylpurinethione (111.17) 
was redissolved in 1 M sodium hydroxide (40 ml) and 2-chloro-
N,N-dimethylethylamine hydrochloride (1.0 g) was added. 
After stirring at 25 0 for 2 h, chloroform extraction and 
evaporation of the extract gave the product (111.18) 
83 
o (52%), m.p. 182-183 (from ethyl acetate) (Found: C, 
55.8; H, 5.2; N, 27.7. C14H16N6S requires C, 56.0j 
H, 5. 4; N, 28. 0 %). N . m. r. (CDC1 3 ) 8. 59, d, H 2", 6"; 
8.18, d, H 3",5"; 8.12, s, H 8'; 3.69, t, H 2; 2.97, 
t, H 1; 2.47, s, NMe 2 . 
, 
N,N-Dimethyl-2-(8'-phenylpurin-6'-ylthio)ethylamine (111.20) 
Alkylation of 8-phenylpurine-6(lH)-thione lo (111.19) 
(0.5 g) with 2-chloro-N,N-dimethylethylamine hydrochloride 
(0.5 g), as for the isomer (111.6), gave the product 
(111.20) o (71%), m.p. 232 (from ethanol) (Found: C, 60.5; 
H, 5. 7; N, 22. 9. CIS H 1 7 N 5 S require s C, 60. 2; H, 5. 7 ; 
N, 23. 4 %). N . m. r. (1 M DCl) 8. 92, s, H 2'; 7. 83, m, Ph; 
7 . 4 7, m, Ph; 3. 7 7, t, H 2; 3. 1 0, s, NMe 2; 2. 8 0, t, H 1.. 
2-Chloro-8-phenylpurine (111.25) 
(A) 2-Chloropyrimidine-4,5-diamine 11 (111.21) (1.40 g), 
benzaldehyde (1.20 g) and ethanol (30 ml) were boiled 
under reflux for 1 h and then cooled. F il tra tion of the SUSpe)")~'DYl ~ve 
5-benzylideneamino-2-chloropyrimidin-4-amine (111.22) 
o (82 %), m.p. 229 (from ethanol) (Found: C, 57. 1; H, 3. 8 ; 
Cl, 15.2; N, 23.7. CllH9ClN4 requires C, 56.8; H, 3.9; 
Cl, 15.2; N, 24.1 %). 
The Schiff base (111.22) (1.0 g), N-bromosuccinimide 
(0.9 g) and chloroform (30 ml) were boiled under reflux 
for 90 min. The residue from evaporation was triturated 
with water to give the chloropurine (111.25) (75 %), 
o . 
m.p. 285 (from ethanol) (Found: C, 56.7; H, 3.2; 
,( 
N, 23.7. CllH7ClN4 requires C, 57.3; H, 3.1; N, 24.1%). 
N.m.r. [(CD3)280] 8.94, s, H 6; 8.20, m, Ph; 7.66, m, P·h. 
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(B) 4,5-Diaminopyrimidin-2(lH)-one 12 (111.23) (1.2 g), 
benzoyl chloride (1.5 g) and 1 M sodium hydroxide were 
stirred vigorously for 30 min and then acidified to pH 5. 
Filtration gave N-(4-amino-l,2-dihydro-2-oxopyrimidin-5-yl)-
ben z am ide ( I I I . 2 4 ) ( 8 7 %), m. p . 3 2 1 0 ( dec .) ( from 
methoxyethanol) (Found: C, 57. 0; H, 4. 5; N, 24. 1 . 
C 11 H ION 4 O2 r e qu ire s C, 57. 4; H, 4. 4; N, 2 4 . 3 %) . 
N . m. r . [( CD 3) 280] 9. 49, s, H 6; 7. 95, m, Ph; 7. 55, m, 
Ph; 7.00, s, br, NH. 
The amide (111.24) (0.5 g) and P-dichloro-P-phenyl-
phosphine oxide (10.0 g) were heated under reflux for 6 h. 
The cooled mixture was added to ice water and allowed to 
stand in the refrigerator 
~~ 
provedAidentical with the 
for 12 h. The solid (76%) wClS 
product (111.25) in (A) above. 
8-Phenylpurine-2(lH)-thione (111.26) 
The above chloropurine (111.25) (0.80 g), thiourea 
(0.30 g) and ethanol (20 ml) were boiled under reflux 
the S(7/Jlt"(}J1 
for 1 h. After coolingl\ the thione (111.26) (79 %) was 
filtered off. It had m.p. 303 0 (from ethanol) (Cf 13 >300 0 ; 
5 %) (Found: C, 57.5; H, 3.2; N, 24.4. Calc. for Cl1H8N48: 
C, 57.9; H, 3.5; N, 24.5 %). N.m.r. [(CD 3 ) 280] 9.01, s, 
H 6; 8.21, m, Ph; 7.62, m, Ph. 
.. 
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6-(2'-Dimethylaminoethyl)amino-5-nitro-2-phenylpyrimidine-
4-amine (III.28) 
6-Chloro-5-nitro-2-phenylpyrimidin-4-amine 14 (III.27) 
(2.0 g) and 2-dimethylaminoethylamine (6.0 g) were boiled 
under reflux for 20 min. The cooled mixture was diluted 
with water and filtration gave the nitropyrimidine (III.28) 
o (8%), m.p. 168 (from ethanol) (Found: C, 53.0; H, 5.8; 
N, 26.7. C14H18N602·0.75 H2 0 requires C, 53.3; H, 6.2; 
N, 26~6%). N.m.r. (CDC1 3 ) 8.38, m, Ph; 7.48, m, Ph; 
3 . 8 4, q, H'; 2. 6 2, t, H 2'; 2. 32, s, NMe 2; 1. 58, s, NH. 
6-{2'-Dimethylaminoethyl)amino-2-phenylpyrimidine-4,5-
diamine Dihydrochloride (III.29) 
The above nitropyrimidine (III.28) (2.0 g) was stirred 
In water (40 ml) at 800 while sodium di~hionite (10.0 g) 
4 
was added during 5 min. The mixture was allow€d to cool 
with stirring and then adjusted to pH 10. The suspension 
was extracted with ether and evaporation of the extract 
gave the crude base (64 %) which was characterized as the 
4,5-diaminopyrimidine dihydrochloride (I1I.29) m.p. 266 0 
(from ethanol) (Found: C, 48. 5; H, 6. 6; N, 24. 1 . 
C14H20N6·2HCl requires C, 48.7; H, 6.4; N, 24.3 %). 
N.m.r. (D2 0) 7.97, m, Ph; 7.69, m, P.h; 4.06, q, HI'; 
3 . 50, t, H 2'; 2. 98, ,s, NMe 2 . 
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N-(2'-Dimethylaminoethyl)-2-phenylpteridin-4-amine (111.30) 
and its 6,7-Dimethyl Derivative (111.31) 
The above crude base (111.29) (0.5 g), 40 % aqueous 
glyoxal (0.5 g) [or diacetyl (0.3 g)], and ethanol (10 ml) 
were heated under reflux for 1 h. The residue from 
evaporation in a vacuum was triturated with water and 
filtration gave, respectively, the pteridineamine (111.30) 
o (52%), m.p. 173 (from acetone) (Found: C, 65. 2; H, 6. 2 ; 
N, 28.4. C16H18N6 requires C, 65.3; H, 6.2; N, 28.5 %). 
[N. m. r. (CDC1 3 ) 8. 97, d, H 6; 8. 78, d H 7; 8. 60, m, Ph; 
7 . 53, m, Ph; 3. 86, q, HI'; 2. 70, t, H 2'; 2. 36, s, NMe 2 ] 
or the dimethylpteridinamine (111.31) (61 %), m.p. 1570 
(from acetone) (Found: C, 66.0; H, 6.91; N, 26.0. 
C18H22N6 requires C, 67.0; H, 6.9; N, 26.1 %) [N.m.r. 
(CDC1 3 ) 8.67, m, Ph; 7.46, m, Ph; 3 . 86, q, HI' ; 2.73, s, 
6-Me; 2.67, s, 7-Me; 2.67, t, H 2'; 2.35, s, NMe 2 ] . 
4-Methylthio-2-phenylpteridine (111.35) and 6,7-Dimethyl-4-
methylthio-2-phenylpteridine (111.36) 
5,6-Diamino-2-phenylpyrimidine-4(3H)-thione 1 4 (111.32) 
(1.0 g) 40 % aqueous glyoxal (1.0 g) and water (20 ml) were 
heated under reflux for 1 h. Cooling and filtration 
gave 2-phenylpteridine-4(3H)-thione (111.33) (54 %), m.p. 
>225 0 (dec) (from ethanol) (Found: C, 59.9; H, 3.5; 
N, 23.3. C12H8N4S requires C, 60.0; H, 3.4; N, 23 . 3% ). 
N.m.r. [(CD3)2S0] 9.07, d, H 6; 8.87, d, H 7 ; 8 .1 9 , m, Ph; 
7.61, m, Ph. The same substrate (1.0 g),diacetyl (0.5 g ) 
and 95 % ethanol (20 ml) were heated under reflux for 1 h. 
The residue from evaporation was diluted with a little 
water to give 6,7-dimethyl-2-phenyl-4(3H)-thione (111.34) 
o (58%), m.p. >210 (dec.) (from ethanol) (Found: C, 62. 6 ; 
H , 4. 4; S, 11. 7 . C 14 H 12 N 4 S r e qu ire s C, 6 2 . 7; H, 4. 5 ; 
S,11.9%). N.m.r. [(CD3)2S0] 8.17, m, Ph; 7.59, m, Ph; 
2.66, s, 6,7-Me2 . 
Each thione (0.5 g), methyl iodide (1.0 ml) and 1 M 
sodi urn hydroxide ( 2 0 ml) were shaken at 25 0 f 'or 2 h. 
Refrigeration gave, respectively, the thioether (111.35) 
o (92%) m.p. 189 (from ethanol) (Found: C, 61.6; H, 3.9; 
N, 22.0. C13H10N4S requires C, 61.4; H, 4.0; N, 22.0%). 
[N.m.r. in (CD3)2S0 : 9.29, d, H 6; 8.98, d, H 7; 8.64, m, 
Ph; 7.62, m, Ph; 2.81, s, Me] and its 6,7-dimethyl 
derivative (111.36) o (97%), m.p. 163 (from ethanol) 
(Found: C, 61.2; H, 4 . 8; N, 19.0. C15H14N4S.0.5 H2 O 
requlres C, 61.8; H, 5.2; N, 19.2%) " N.m.r. [ (CD 3 ) 2S0 J 
8.59, m, Ph; 7.59, m, Ph; 2.76, s, SMe; 2.75, s, 6-Me; 
2.71, s, 7-Me 
• 
2-Chloro-6,7-dimethyl-4-phenylpteridine (111.38) 
2-Chloro-6-phenylpyrimidine-4,5-diamine 11 (111.37) 
(0.5 g), diacetyl (0.2 g) and 50% aqueous ethanol (20 ml) 
were heated under reflux for 2 h and then refrigerated 
to give the chloropteridine (111.38) (57%), m.p. 185-1860 
(from ethanol) (Found: C, 60. 5; H, 3. 9; N, 19. 5 . 
C14HllC1N4. 0.5 H2 0 requires C, 60.1; H, 4.3; N, 20.0 %). 
N.m.r. [(CD3)2S0] 8.33, m, Ph; 7.66, m, Ph; 2.80, s, 
6-Me; 2.75, s, 7-Me. 
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2-Methylthio-4-phenylpteridine (111.39) and 6,7-Dimethyl-
2-methylthio-4-phenylpteridine (111.40) 
2-Methylthio-6-phenylpyrimidine-4,5-diamine (111.11) 
(0.6 g), ethanol (20 ml) and 40% aqueous glyoxal (0.6 g) 
or diacetyl (0.2 g) were , heated under reflux for 1 hand 
then refrigerated to give, respectively, the pteridine 
o (111.39) (68%), m.p. 176 (from ethanol) (Found: C, 61.2; 
H, 3.9; N, 21.9 C13H10N4S requires C, 61.4; H, 4.0; 
N, 22.0%) [N.m.r. in (CDj) 2S0: 9.20, d, H 6; 9.02, d, H 7; 
8.24, m, Ph; 7.6, m, Ph; 2.71, s, SMe] and the 
) 
dimethylpteridine (111.40) (73%), m.p. 1690 (from ethanol) 
(Found: C, 63.5; H, 5.0; N, 19.8 C15H14N4S requires 
C, 63.8; H, 5.0; N, 19.8%). [N.m.r. in (CD 3 ) 2S0: . 8.28, 
m , Ph; 7. 5 9, m , Ph; 2. 7 5, s, S Me; 2. 6 9, s , 6 - Me, 2. 6 7, s, 
7-Me] . 
N-(2'-Dimethylaminoethyl)-2-phenylquinazolin-4-amine 
(111.43) 
4-Chloro-2-phenylquinazoline 1 5 (111.41) (1.0 g) and 
2-dimethylaminoethylamine (5 g) were boiled under reflux 
for 2 h. The excess amine was removed by distillation 
and the residue was diluted with water (8 ml) and adjusted 
to pH 10. The residue from evaporating an ether extract 
was dissolved in ethanol (10 ml) and to this was added 
ethanolic 5 M hydrogen chloride (4.0 ml). After warming 
momentarily to attain homogeneity, refrigeration gave the 
product (111.43) as dihydrochloride (89%), m.p. 273 0 
(from ethanol) (Found: C, 59.1; H, 6.5; N, 15.3. 
C1SH20N4.2HCl requires C, 59.2; H, 6.1; N, 15.3%). 
A dihydrochloride with the same melting point has been 
described previously17 as a sesquihydrate. 
N-(2'-Dimethylaminoethyl)-4-phenylquinazolin-2-amine 
(III.44) 
Similar treatment of 2-chloro-4-phenylquinazoline 16 
(III.42) gave the product (III.44) as hydrochloride (91%), 
m.p.234-236° (Found: C, 61.0; H, 6.2; N, l5.S. 
ClSH20N4-1.7 HCl requires C, 61.1; H, 6.3; N, l5.S%; 
this composition was maintained during several 
recrystallizations from ethanol) . 
N,N-Dimethyl-2-(2'-phenylquinazolin-4'-ylthio)ethylamine 
I 
S9 
(III.46) and N,N-Dimethyl-3-(2'-phenylquinazolin-4'ylthio)-
propyl amine (III.47) 
~ 
2-Phenylquinazoline-4 (3H) -thione 18 (III.45) (1. Og), 
2-chloro-N,N-dimethylethylamine hydrochloride (O.S g) and 
2 M sodium hydroxide (20 ml) were stirred at 25 0 for 2 h. 
The solution was adjusted to pH S and extracted with ether. 
After dehydration of the extract, 5 M ethanolic hydrogen 
chloride (4.0 ml) was added and refrigeration gave the 
ethylamine (III.46) as hydrochloride (SS %), m.p. 21S o 
(from ethanol) (Found: C, 62.1; H, 5.S; N, 11.7. 
ClSH19N3S.HCl requires C, 62.5; H, 5.S; N, 12.1 %). 
dimetnyl 
The use o f 3-c,hloro-N, N~ropylamine hycLrochloYicle in the 
above preparation afforded the homologous propylamine 
(III.47), as hydrochloride (67 %), m.p. 126-l2So (from 
ethanol) (Found: C, 63.4; H, 6.3; N, 11.S. C19H21N3S 
requlres C, 63. 4; H, 6. 2; N, 11.7 %). 
I" 
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N,N-Dimethyl-2-(4'-phenylquinazolin-2'-ylthio)ethylamine 
(111.49) and N,N-Dimethyl-3-(4'-phenylquinazolin-2'-ylthio)-
propyl amine (111.50) 
S-Alkylation of 4-phenylquinazoline-2(lH)-thione 19 
(111.48), as for the above isomers (111.46) and 1(111.47), 
gave the ethylamine (111.49) as hydrated hydrochloride (91%), 
o 
m.p. 208 (from ethanol) (Found: C, 61. 5; H, 5. 8; N, 12. 0 . 
C18H19N3S.0.25 H2 0.HCl requires C, 61.7; H, 5.9; N, 12.0%). 
and the propylamine (III~50) as hydrochloride (54%), m.p. 
o 173-174 (from ethanol) (Found: C, 63. 2; H, 6. 1; N, 11. 4 . 
C19H21N3S.HCl requires C, 63.4; H, 6.2; N, 11.7 %). 
N,N-Dimethyl-2-[2'-(pyridin-4'-yl)quinazolin-4'-ylthi0]-
ethylamine (111.53) 
pyridine-4-carboxamidinium chloride 9 , (111.13) (3.0 g) 
and anthranilic acid (1.0 g) were fused together at 
o 180-190 for 30 mln. The cooled residue was triturated 
with water and filtered to give 2-(pyridin-4'-yl)quinazolin-
o 4-(3H)-one (111.51) (76 %), m.p. 283 (from ethanol) 
(Found: C, 69.5; H, 4.0; N, 18.8. Calc. for C13H9N3 0: 
o C, 69.8; H, 4.1; N, 18.8%) (cf. 290-294 for the same 
material made by a less convenient route 17 ). The 
quinazolinone (1.0 g), phosphorus pentasulfide (1.0 g) and 
pyridine (40 ml) were warmed slowly to boiling and then 
kept under reflux for 1 h. The cooled mixture was auded 
to ice water (150 ml) and allowed to stand at 50 for 24 h. 
The crude thione (111.52) (Cf. 17 , 20 ) was dissolved in 
foy-.2 h 
1 M sodium hydrox-ide (40 rnl) and stirredj\ with 2-chloro-
N, N-dimethylethylamine hydr-ochloricle . Ether extraction and 
r:l~ 
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evaporation of the extract gave the required ethy1amine 
(111.53) (40%), m.p. 92-93 0 (from light petroleum) 
(Found: C, 65.5; H, 5.9; N, 18.0. C17H18N4S requires 
C, 65.8; H, 5.8; N, 18.0%). N.m.r. (CDC1 3 ) 8.80, d, 
H 2",6"; 8.43, d, H 3",5"; 7.84, m, H 5'-8'; 3.66, t, 
H 1; 2. 80, t, H 2; 2. 38, s, NMe 2 · 
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CHAPTER IV 
BIOLOGICAL ACTIVITIES 
IV-l Biological Results 
The pyrimidinylpurine, phenylpurine, pyrimidinyl-
pteridine, phenylpteridine, and phenylquinazoline 
derivatives, described in CHAPTER II and III and listed 
in Tables 1-4, were evaluated* as amplifiers of 
phleomycin-G against an in vitro culture of Escherichia 
coli. Caffeine was taken as Q standard, with I-star 
activity at 2mM or 0.5mM concentration. 
Table 1 lists the activities for the 2-(pyrimidin-
4' -yl) purines (11.20-22,24,25,27). Among these compounds, 
(11.21) showed only moderate activity (3-star), (11.22,24,27) 
showed mediocre activity, and (11.20,25) were too poorly 
soluble for effective testing. 
Table 2 shows activities for some phenylpurines 
(111.4,6,9,12,20), and one 2-(pyridin-4'-yl)purine (111.18). 
The best of these compounds was (111.6) with 'high activity' 
(4-star) i its analogues (111.4,9,20) showed only 2-star 
activity, and the 2-pyridin-4'-yl analogue (111.18) could 
not be evaluated in the standard test system because of 
its intrinsic antibacterial activity. 
* Such assays were kindly done by Mrs D. Kavulak, 
CSIRO Molecular & Cellular Biology Unit, using a 
method already described. l 
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In Table 3 are shown activities for a 
2-(pyrimidin-4'-yl)pteridine (11.33) and some analogous 
phenylpteridines (111.30,31,35,36,39,40). Of these, 
only (111.31) showed moderate 3-star activity; (111.30,36) 
showed I-star activity; the methylthio analogues 
(111.35,39,40) were too poorly soluble for testing; and 
the pyrimidinylpteridine (11.33) could not be evaluated 
because of antibacterial activity. 
Table 4 shows the results for some phenylquinazolines 
(111.43,44,46,47,49,50) and for the 2-pyridin-4'-yl 
analogue (111.53). Although (111.46) showed high 4-star 
activity, its analogues (111.44,49,50) showed only low to 
moderate (2-star) activities, (111.43) showed minimal 
I-star activity, and the 2-pyridin-4'-yl analogue (111.53) 
could not be evaluated on account of its antibacterial 
activity. 
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Compound 
(11.20) 
(11.21) 
(11.22) 
(11.24) 
(11.25) 
(11.27) 
Table 1 
R2 
N~N /~ ~~~R3 
N INN 
y,N 1 
R4 
1 
Rl R 2 R3 
NMe 2 SMe H 
NMe 2 SCH 2CH 2NMe 2 H 
OMe NHCH 2CH 2NMe 2 H 
NMe 2 NH2 SCH 2CH 2NMe 2 
NMe 2 NHAc SCH 2CH 2NMe 2 
OMe NH2 I SCH 2CH 2NMe 2 
t Measured at 2rnM 
for definitions of activity 
see D. J. Brown et ale (1981) 1 
A Solubility precluded measurement 
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R4 Activityt 
H -A 
H *** 
H * 
H * 
Ac -A 
H ** 
Compound 
(111.4) 
(111.6) 
(111.9) 
(111.12) 
(111.18) 
(111.20) 
Table 2 
R2 
N/ 
1 I~ R~N 
Rl 
Ph 
Ph 
N 
Nl-R3 
H 
R 2 
NHCH 2CH 2NMe 2 
SCH 2CH 2NMe 2 
, 
R ::l 
H 
I H 
Ph NH2 SCH 2CH 2NMe 2 
, 
SMe Ph H 
pyridin-4-yl SCH 2CH 2NMe 2 H 
H SCH 2CH 2NMe 2 Ph 
- - - - -- - - ----
t Measured at O.SmM 
A At 2mM 
B At < O.SmM (saturated) against 
caffeine at O.SmM 
C Intrinsic antibacterial activity 
precluded measurement 
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Activityt 
**A 
**** 
**B 
OB 
C 
-
** 
..-T. 
j, 
, 
,~ 
~ I . 
~: 
, 
Ii 
II 
II 
lii;t 
J 
It 
I\~ 
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Compound 
(11.33) 
(111.30) 
(111.31) 
(111.35) 
(111.36) 
(111.39) 
(111.40) 
Table 3 
R2 
I 
N~ lCNt R3 1~ I /' R3 
R N N 
Rl R2 R3 
2-methoxy- NHCH 2CH 2NMe 2 H pyrimidin-
4-yl 
Ph NHCH 2CH 2NMe 2 H 
Ph NHCH 2CH 2NMe 2 Me 
Ph SMe H 
Ph SMe Me 
SMe Ph H 
SMe Ph Me 
t Measured at O.SmM 
A At 2rnM 
B At < O.SrnM (saturated) against 
caffeine at O.SmM 
C Intrinsic antibacterial activity 
precluded measurement 
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Activityt 
A,C 
* 
*** 
OB 
*A 
OB 
OB 
III""'1j 
~ 
(111.43) 
(111.44) 
(111.46) 
! 
(111.47) 
I: (111.49) 
(111.50) 
(111.53) 
II 
III 
.I 
r. 
I~ ! 
Table 4 
Ph NHCH 2CH 2NMe 2 
NHCH 2CH 2NMe 2 Ph 
Ph SCH 2CH 2NMe 2 
Ph SCH 2CH 2CH 2NMe 2 
SCH 2CH 2NMe 2 Ph 
SCH 2CH 2CH 2NMe 2 Ph 
pyridin-4-yl SCH 2CH2NMe 2 
t Measured at 0.5mM 
A Intrinsic antibacterial activity 
precluded measurement 
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** 
**** 
A 
** 
** 
A 
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IV-2 Discussion 
The annelation (fusion) of a imidazole ring onto a 
2,4'-bipyrimidine bearing a suitable side chain did not 
lmprove activity. Thus, the 2-(pyrimidin-4'-yl)purine 
,I 
I ~.t 
(11.21) with 3-star activity and its analogue (11.22) 
with I-star activity differed only slightly from 
comparable 2,4'-bipyrimidines 2 such as (IV.2) with 
3-star and (IV.3) with 2-star activity (see Scheme IV-I). 
ill 
On the other hand, the addition of an (unfused) 
pyrimidine ring to a purine improved activity, so that 
(11.21) with 3-star proved much more active than the 
comparable purine (IV.5) with I-star activity. 2 
Relocation of the basic side chain from the 6- to the 
8-position in the pyrimidinylpurines had a mildly 
deleterious effect. Thus, the 8-thioether (11.24) showed 
I-star activity compared to the 3-star activity of the 
analogous 6-thioether (11.21) i another 8-thioether (11.27) 
showed a marginal improvement from 1- to 2-star activity 
when compared with its 6-analogue (11.22), but this was 
probably on account of the additional change from a 
nitrogen- to a more desirable sulfur-linkage of the side 
chain. 1 The acetyl derivative (11.25) was very poorly 
soluble. The effect of similarly annelating a pyrazine 
ring onto a 2,4'-bipyrimidine system remains unknown 
because the 2-(pyrimidin-4'-yl)pteridine (11.33), so 
formed, proved to have intrinsic antibacterial activity 
II 
and hence could not be tested effectively in the only 
screen available . " 1 
IN 
I' 
SCH2CONH2 
/ 
l:N I 
I NyN 
NMe2 
(IV. 1) 
R 
Me 
(IV.2; R=NHCH 2CH 2NMe 2 ) 
(IV.3; R=SCH 2CH 2NMe 2 ) 
R 
Me 
(III.la; X=N, R=SCH 2CH 2NMe 2 ) 
(111.2 . X=CH, R=SCH 2CH 2NMe 2 ) , 
( IV.4 X=CH, R=NHCH 2CH 2NMe 2 ) 
R 
.;- .... " 
\ 
I Het. I 
'- - .,.; 
/ 
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(IV.S; R=SCH 2CH 2NMe 2 , 
Het=imidazole) 
(IV.6; R=SCH 2CONH 2 , 
Het=benzene) 
R 
--, 
,,; \. 
\ 
Het. I 
I 
/ 
'- ...-' 
I 
N~ N Y 
R 
(I I. analogues) 
(III. 
R 
/- .... , 
\ 
Het. I 
J 
/ 
'-_/ 
analogues) 
Scheme IV-l 
r". 
I' I 
I 
1 
J 
I , 
I 
I~ 
I 
[; 
I 
I~ 
I~ 
102 
It was observed recently that the replacement of 
one pyrimidine ring in a bipyrimidine by a benzene, 
pyridine, or thiophene ring [to give a phenyl-, (111.2), 
pyridin-4'-yl (111.1a), or thienyl-pyrimidine] enhanced 
activity markedly3-5(see CHAPTER 111-1, Introduction). 
The effect of similarly adding an (unfused) benzene ring 
to a purine (to give a phenylpurine) showed an improvement 
from (11.21) with 3-star, to (111.6) with 4-star activity 
(Table 2); on the other hand, the annelation of a (fused) 
imidazole ring onto a phenylpyrimidine showed a decrease 
in activity from (111.2) with 5-star, to (111.6) with 
4-star activity. In contrast, the phenylpyrimidine 
bearing an NH-linked side chain (IV.4) 3 showed marginal 
improvement from 1- to 2-star activity compared with 
(111.4) . The pyridin-4'-yl analogue (111.18) could not 
be evaluated because of its intrinsic antibacterial 
activity, and the phenylpurines (111.20), (111.4), and 
(111.9) showed only 2-star activities. The methylthio 
analogue (111.12) proved virtually inactive (Table 2). 
The 2-phenylpteridine bearing an NH-linked side chain 
at the 4-position (111.30) showed only l-star activity 
but is 6,7-dimethyl homologue (111.31) showed significant 
improvement to the 3-star range; although the related 
methylthiopteridines (111.35), (111.36), (111.39) and 
(111.40) showed minimal activities, it is clear that the 
4-dimethylaminoethylthio analogue of the active amplifier 
(111.31) should be prepared for evaluation. The 
annelation of a (fused) pyrazine ring onto phenyl-
pyrimidine bearing an NH-linked side chain improved 
\ 
103 
activity: although (111.30) as well as (IV.4) showed 
only I-star activity, the 6,7-dimethyl homologue (111.31) 
showed marked improvement to 3-star activity (cf. the 
effect of added C-methyl groups on the activity of 
alkylthiopurines 6 ) • 
The best quinazoline dey-OJ Vett ,ye was that wi th a 
2-phenyl group and a sulfur-linked side chain in the 
4-position (111.46) (4-star activity: see Table 4); 
the annelation of a (fused) benzene ring onto the 
phenylpyrimidine (111.2) was accompanied by a decrease 
in activity from 5- to 4-star in (111.46), but the 
addition of an (unfused) benzene ring onto the 
quinazoline (IV.6) 7,8 improved activity from 3- to 4-star. 
The isomer (111.49) and its homologue (111.50) showed 
only 2-star activities, while the NH-linked analogues 
(111.43) and (111.44) showed 1- and 2-star activity, 
respectively. The related compound (111.47) and the 
2-pyridin-41-yl analogue (111.53) of the prime amplifier 
(111.46) exhibited sufficient antibacterial activity to 
preclude testing. This was disappointing because 
(111.47) was expected to show high activity, being a 
fused analogue of (III.la) with 5-star activity. The 
2-(pyridin-4 1-yl)purine (111.18) likewise showed 
sufficient antibacterial activity to preclude testing. 
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INDEX TO COMPOUNDS* 
N-[9-Acetyl-8-(2"-dimethylaminoethyl)thio-
2-(2'-dimethylaminopyrimidin-4'-yl)purin- 6 -
yl]acetamide 
N-(4-Amino-l,2-dihydro-2-oxopyrimidin-5-yl)-
benzamide 
6-Amino-2'-dimethylamino-2,4'-bipyrimidin-
4(3H)-one 
6-Amino-2'-dimethylamino-5-nitroso-2,4'-
bipyrimidin-4(3H)-one 
6-Amino-2-(2'-dimethylaminopyrimidin-4'-yl)-
purine-8(7H)-thione 
6-Amino-2'-methoxy-5-nitroso-2,4'-bipyrimidin-
4(3H)-one 
6-Amino-2-(2'-methoxypyrimidin-4'-yl)purine-
8(7H)-thione 
4-Amino-5-nitroso-2-(pyridin-4'-yl)pyrimidin-
4(3H)-one 
6-Amino-2-phenylpurine-8(7H)-thione 
5-Benzylideneamino-2-chloropyrimidin-4-amine 
6-Chloro-2-(2'-dimethylaminopyrimidin-
4'-yl)purine 
2-Chloro-6,7-dimethyl-4-phenylpteridine 
4-Chloro-2-(2'-methoxypyrimidin-4'-yl)pteridine 
6-Chloro-2-(2'-methoxypyrimidin-4'-yl)purine 
6-Chloro-5-nitro-2-phenylpyrimidin-4-amine 
2-Chloro-8-phenylpurine 
*New compounds in italic type. 
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55 
84 
46 
47 
54 
48 
55 
81 
80 
83 
51 
87 
58 
52 
85 
84 
6-Chloro-2-phenylpurine 
2-Chloro-6-phenylpyrimidine-4,5-diamine 
2-Chloro-4-phenylquinazoline 
4-Chloro-2-phenylquinazoline 
2-Chloropyrimidine-4-carbonitrile 
2-Chloropyrimidine-4,5-diamine 
5,6-Diamino-2'-dimethylamino-2,4'-
bipyrimidin-4(3H)-one 
5,6-Diamino-2'-methoxy-2,4'-bipyrimidin-
4(3H)-one 
4,5-Diamino-6-~henylpyrimidine-2(lH)-thione 
5,6-Diamino-2-(pyridin-4'-yl)pyrimidin-
4(3H)-one 
4,5-Diaminopyrimidin-2(lH)-one 
5,6-Diamino-2-phenylpyrimidine-4(3H)-thione 
2'-Dimethylamino-2,4'-bipyrimidine-4,5,6-
triamine 
6-(2'-Dimethylaminoethyl)amino-5-nitro-
2-phenylpyrimidin-4-amine 
6-(2'-Dimethylaminoethyl)amino-2-phenylpyrimidine-
4,5-diamine dihydrochloride 
N-(2'-Dimethylaminoethyl)-6,7-dimethyl-2-
phenylpteridin-4-amine 
N-(2"-Dimethylaminoethyl)-2-(2'-methoxypyrimidin-
4'-yl)pteridin-4-amine 
N-(2"-Dimethylaminoethyl)-2-(2'-methoxypyrimidin-
4'-yl)purin-6-amine 
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79 
87 
89 
88 
45 
83 
49 
49 
81 
81 
84 
86 
50 
85 
85 
86 
58 
53 
N-(2'-Dimethylaminoethyl)-2-phenylpteridin-
4-amine 
N-(2'-Dimethylaminoethyl)-2-phenylpurin-
6-amine 
N-(2'-Dimethylaminoethyl)-2-phenylquinazolin-
4-amine dihydrochloride 
N-(2'-Dimethylaminoethyl)-4-phenylquinazolin-
2-amine 
8-(2"-Dimethylaminoethyl)thio-2-(2'-
dimethylaminopyrimidin-4'-yl)purin-
6-amine 
8-(2"-Dimethylaminoethyl)thio-2-(2'-
methoxypyrimidin-4'-yl)purin-6-amine 
8-(2'-Dimethylaminoethylthio)-2-phenylpurin-
6-amine 
2'-Dimethylamino-5-nitroso-2,4'-bipyrimidine-
4,6-diamine 
2-Dirnethylarninopyrirnidine-4-carbonitrile 
2-Dimethylaminopyrimidine-4-carboxamidinium 
chloride 
2-(2'-Dimethylaminopyrimidin-4'-yl)pteridin-
4(3H)-one 
2-(2'-Dimethylaminopyrimidin-4'-yl)purin-
6(lH)-one 
2-(2'-Dimethylaminopyrimidin-4'-yl)purine-
6(lH)-thione 
2-[2'-(2"-Dimethylaminopyrimidin-4"-yl)purin-
6'-ylthio)-N,N-dimethylethylamine 
107 
86 
79 
88 
89 
54 
56 
80 
48 
45 
45 
56 
50 
52 
53 
2-(2'-Dimethylaminopyrimidin-4'-yl)quinazolin-
4(3H)-one 
2-(2'-Dimethylaminopyrimidin-4'-yl)quinazolin-
4(3H)-thione 
5-(2'-Dimethylaminopyrimidin-4'-yl)-(lH)-
v-triazolo[4,5-d]pyrimidin-7(6H)-one 
6,7-Dimethyl-2-methylthio-4-phenylpteridine 
6,7-Dimethyl-4-methylthio-2-phenylpteridine 
N,N-Dimethyl-4-(6'-methylthiopurin-2'-yl)-
pyrimidin-2-amine 
6,7-Dimethyl-2-phenylpteridine-4(3H)-thione 
N,N-Dimethyl-2-(2'-phenylpurin-6'-ylthio)-
ethyl amine 
N,N-Dimethyl-2-(8'-phenylpurin-6'-ylthio)-
ethylamine 
N,N-Dimethyl-2-(2'-phenylquinazolin-4'-
ylthio)ethylamine 
N,N-Dimethyl-2-(4'-phenylquinazolin-2'-
ylthio)ethylamine 
N,N-Dimethyl-3-(2'-phenylquinazolin-4'-
ylthio)propylamine 
N,N-Dimethyl-3-(4'-phenylquinazolin-2'-
ylthio)propylamine 
N,N-Dimethyl-2-[2'-(pyridin-4"-yl)purin-
6'-ylthio]ethylamine 
N,N-Dimethyl-2-[2'-(pyridin-4"-yl)quinazolin-
4'-ylthio]ethylamine 
108 
59 
59 
57 
88 
86 
52 
87 
79 
83 
89 
90 
89 
90 
82 
90 
Ethyl 3-amino-2-cyano-3(2'-dimethylamino-
pyrimidin-4'-yl)acrylate 
Ethyl 2-cyano-2-hydroxyiminoacetate 
a -Hydroxyiminomalononitrile 
2'-Methoxy-2,4'-bipyrimidine-4,5,6-triamine 
2'-Methoxy-5-nitroso-2,4'-bipyrimidine-
4,6-diamine 
2-Methoxypyrimidine-4-carboxamidinium chloride 
2-(2'-Methoxypyrimidin-4'-yl)pteridin-
4(3H)-one 
2-(2'-Methoxypyrimidin-4'-yl)purin-6(lH)-one 
5-(2'-Methoxypyrimidin-4'-yl)-(lH)-v-
triazolo[4,5-d]pyrimidin-7(6H)-one 
2-Methylthio-4-phenylpteridine 
4-Methylthio-2-phenylpteridine 
2-Methylthio-6-phenylpurine 
2-Methylthio-6-phenylpyrimidine-4,5-diamine 
2-Phenylpteridine-4(3H)-thione 
2-Phenylpurine-6(lH)-thione 
8-Phenylpurine-2(lH)-thione 
8-Phenylpurine-6(lH)-thione 
2-Phenylpyrimidine-4,S,6-triamine 
2-Phenylquinazoline-4(3H)-thione 
4-Phenylquinazoline-2(lH)-thione 
Pyridine-4-carboxamidinium chloride 
2-(Pyridin-4'-yl)purin-6(lH)-one 
2-(Pyridin-4'-yl)purine-6(lH)-thione 
2-(Pyridin-4'-yl)quinazolin-4(3H)-one 
2-(Pyridin-4'-yl)quinazoline-4-(3H)-thione 
109 
46 
47,48,81 
48 
50 
49 
46 
56 
51 
57 
88 
86 
81 
81 
86 
79 
84 
83 
80 
89 
90 
81,90 
82 
82 
90 
90 
